Navigation Links
GENFIT Selected by Windhover for the 2011 'Top Biopharma Projects To Watch'

LILLE, France and CAMBRIDGE, Mass., Oct. 25 /PRNewswire/ -- GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announced that it has been selected by Windhover as one of the "Top Biopharma Projects To Watch" in 2011 in the cardiovascular/metabolic category. This announcement is part of the conference event organized by Elsevier Business Intelligence and Windhover Conferences taking place in Boston from November 2-4, 2010, where GENFIT will be presenting its latest scientific achievements.

"This year's list is handpicked in the six hottest therapeutic areas," said David Cassak, vice president, content, for Elsevier Business Intelligence's publications. "Many of our past winners have gone on to do big deals, and we expect the same from this year's companies."

The Windhover conference annually elects 10 biopharmaceutical companies with high-value assets for partnership in six specific therapeutic areas: cardiovascular/metabolic, oncology, neuroscience, infectious diseases, inflammatory/autoimmune and a category including ophthalmology, orphan diseases, and women's health. 

Dr. Dean W. Hum, chief scientific officer of GENFIT, added,"Being a well recognized company in the U.S. in our specific therapeutic area is a great honor for us. We will present our most advanced drug candidate in the field of diabetes, GFT505, and our specific and innovative approach to the prevention and treatment of cardiometabolic diseases. This will be illustrated by the presentation of other internal research programs, in particular those dedicated to the discovery of early biomarkers and those dealing with the connection between circadian cycle dysregulation and metabolic diseases."

About Windhover:Windhover Information Inc, an Elsevier company, has provided analysis of the healthcare industry to decision-makers at all levels since the founding of its flagship publication, IN VIVO: The Business & Medicine Report, in 1983. Windhover provides its information and analysis in many formats, including print, electronic databases, international conferences and webinars. For more on the company's products and services, please see

About GENFIT:GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases…). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies (SANOFI-AVENTIS, SERVIER, ...), to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase II.  

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 100 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.comContacts:GENFITJean-Francois Mouney – CEO & Chairman of the Management Board+33 (0)3 2016 4000Russo PartnersMartina Schwarzkopf, Ph.D.+1 212 845-4292 / +1 347 591 8785 - martina.schwarzkopf@russopartnersllc.comMilestones – Press RelationsBruno Arabian+33 (0)1 75 44 87 40 / +33 (0)6 87 88 47 26 –

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Zila Inc. Product Selected to Identify Pre-Cancer in Study of Leading Cancer Treatment Chemotherapeutic - ERBITUX
2. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
3. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
4. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
5. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
6. XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
7. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
8. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
9. Jennerex Therapeutic Research Collaboration With Ottawa Hospital Research Institute Selected for $10 Million Grant From Ontario Institute for Cancer Research
10. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
11. Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Post Your Comments:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
Breaking Medicine Technology:
(Date:6/25/2016)... California (PRWEB) , ... June 25, 2016 , ... "With ... fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... customizable and all within Final Cut Pro X . Simply select a ProHand ...
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening ... Talker Award, an essay contest in which patients and their families pay tribute to ... at the 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this ...
(Date:6/24/2016)... ... 2016 , ... National recruitment firm Slone Partners is pleased to ... genomics experience, as Vice President of North American Capital Sales at HTG Molecular ... the sales team in the commercialization of the HTG EdgeSeq system and associated reagents ...
Breaking Medicine News(10 mins):